Topical corticosteroids for atopic eczema: Clinical and cost effectiveness of once-daily vs. more frequent use

British Journal of Dermatology

Volumn 152, Issue 1, 2005, Pages 130-141

  Green, Colin ^a   Colquitt, J L ^a   Kirby, J ^a   Davidson, P ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Atopic eczema; Clinical effectiveness; Cost effectiveness; Frequency; Systematic review; Topical corticosteroids

Indexed keywords

ALCLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE; BETAMETH; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; CLOBETASONE BUTYRATE; CORTICOSTEROID; DIFLUCORTOLONE VALERATE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; FLUTICASONE; FLUTICASONE PROPIONATE; HALCINONIDE; HYDROCORTISONE; HYDROCORTISONE BUTYRATE; MOMETASONE FUROATE; PLACEBO; FLUDROXYCORTIDE;

ARTICLE; ATOPIC DERMATITIS; BURNING SENSATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG POTENCY; EAR NOSE THROAT DISEASE; ERYTHEMA; FOLLICULITIS; HUMAN; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STRIA; SYSTEMATIC REVIEW; ACNE; BURN; DECISION MAKING; DRUG EFFICACY; DRUG RESPONSE; EAR INFECTION; HAIR GROWTH; NOSE INFECTION; OUTCOME ASSESSMENT; PHARYNGITIS; PHOBIA; REVIEW; SKIN ATROPHY; SKIN DISEASE; SKIN TINGLING; TELANGIECTASIA; UNSPECIFIED SIDE EFFECT; XEROSIS;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HEALTH CARE COSTS; HUMANS; TREATMENT OUTCOME;

EID: 13244288021     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06410.x     Document Type: Article

References (32)

1. Topical steroids for atopic dermatitis in primary care. Drug Ther Bull 2003; 41:5-8.
2. Williams HC. On the definition and epidemiology of atopic dermatitis. Dermatol Clin 1995; 13:649-57.
3. Archer CB. The pathophysiology and clinical features of atopic dermatitis. In: Atopic Dermatitis. The Epidemiology, Causes and Prevention of Atopic Eczema (Williams HC, ed.). Cambridge: Cambridge University Press, 2000; 25-40.
4. Emerson RM, Williams HC, Allen BR. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J Dermatol 1998; 139:73-6.
5. Barankin B, DeKoven J. Psychosocial effect of common skin diseases. Can Fam Physician 2002; 48:712-16.
6. Herd RM, Tidman MJ, Prescott RJ, Hunter JAA. The cost of atopic eczema. Br J Dermatol 1996; 135:20-3.
7. Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol 2001; 144:514-22.
8. British National Formulary, no. 47 (March). London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2004.
9. Lagos BR, Maibach HI. Frequency of application of topical corticosteroids: an overview. Br J Dermatol 1998; 139:763-6.
10. Bleehen SS, Chu AC, Hamann I et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol 1995; 133:592-7.
11. Koopmans B, Lasthein AB, Mork NJ et al. Multicentre randomized double-blind study of Locoid Lipocream fatty cream twice daily versus Locoid Lipocream once daily and Locobase once daily. J Dermatol Treat 1995; 6:103-6.
12. National Institute for Clinical Excellence. Scope for the Health Technology Appraisal: Topical Corticosteroids for Atopic Eczema. London: NICE, 2003.
13. Green C, Colquitt J, Kirby J et al. Clinical and cost-effectiveness of once daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation. HTA Monograph 2004, in press.
14. NHS Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness. CRD Report 4, 2nd edn. York: University of York, 2001.
15. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4:1-191.
16. Richelli C, Piacentini GL, Sette L et al. Clinical efficacy and tolerability of clobetasone 17-butyrate 0.5% lotion in children with atopic dermatitis. Curr Ther Res Clin Exp 1990; 47:413-17.
17. Tharp MD. A comparison of twice-daily and once-daily administration of fluticasone propionate cream, 0.05%, in the treatment of eczema. Cutis 1996; 57:19-26.
18. Berth-Jones J, Damstra RJ, Golsch S et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. Br Med J 2003; 326:1367.
19. GlaxoSmithKline. A four week multicentre, double blind study to compare safety and efficacy with an OD and BD administration of fluticasone propionate 0.005% ointment in the treatment of atopic eczema. Report 135L, Protocol no. GL/FLT/002 1995 (Unpublished).
20. Hoybye S, Balk MS, De Cunha BF et al. Continuous and intermittent treatment of atopic dermatitis in adults with mometasone furoate versus hydrocortisone 17-butyrate. Curr Ther Res Clin Exp 1991; 50:67-72.
21. Rajka G, Avrach W, Gartner L, Overgaard-Petersen H. Mometasone furoate 0.1% fatty cream once daily versus betamethasone valerate 0.1% cream twice daily in the treatment of patients with atopic and allergic contact dermatitis. Curr Ther Res Clin Exp 1993; 54:23-9.
22. Marchesi E, Rozzoni M, Pini P, Cainelli T. Comparative study of mometasone furoate and betamethasone dipropionate in the treatment of atopic dermatitis. G Ital Dermatol Venereol 1994; 129:IX-XII.
23. Sudilovsky A, Muir JG, Bocobo FC. A comparison of single and multiple applications of halcinonide cream. Int J Dermatol 1981; 20:609-13.
24. Schiffner R, Schiffner-Rohe J, Landthaler M, Stolz W. Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids. Pharmacoeconomics 2003; 21:159-79.
25. Lamb SR, Rademaker M. Pharmacoeconomics of drug therapy for atopic dermatitis. Expert Opin Pharmacother 2002; 3:249-55.
26. Department of Health. Prescription Cost Analysis, http://www.doh.gov.uk/ stats/pca2002.htm.
27. Reidhav I, Svensson A. Betamethasone valerate versus mometasone furoate cream once daily in atopic dermatitis. J Dermatol Treat 1996; 7:87-8.
28. Furue M, Terao H, Rikihisa W et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003; 148:128-33.
29. Thomas KS, Armstrong S, Avery A et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. Br Med J 2002; 324:768.
30. Ellis CN, Drake LA, Prendergast MM et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003; 48:553-63.
31. Williams H. New treatments for atopic dermatitis. Br Med J 2002; 324:1533-4.
32. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142:931-6.